Yoshie Kobayashi

Dr. Yoshie Kobayashi

Department of Breast Surgery and Oncology, Kure Medical Center, Kure, Hiroshima, Japan
Breast Surgeon, Oncologist, and Physician Researcher

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
YKYoshie Kobayashi
Yoshie Kobayashi
SLSeung-Oe Lim
Seung-Oe Lim
HYHirohito Yamaguchi
Hirohito Yamaguchi

20 April 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
YKYoshie Kobayashi
Yoshie Kobayashi
TKTakayuki Kadoya
Takayuki Kadoya
AAAi Amioka
Ai Amioka
HHHideaki Hanaki
Hideaki Hanaki
SSShinsuke Sasada
Shinsuke Sasada
MOMorihito Okada
Morihito Okada
Wnt5a-induced cell migration is associated with the aggressiveness of estrogen receptor-positive breast cancer Wnt5a-induced cell migration is associated with the aggressiveness of estrogen receptor-positive breast cancer

1 December 2016 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
KAKoji Arihiro
Koji Arihiro
MOMiyo Oda
Miyo Oda
MOMasahiro Ohara
Masahiro Ohara
TKTakayuki Kadoya
Takayuki Kadoya
AOAkihiko Osaki
Akihiko Osaki
YKYoshie Kobayashi
Yoshie Kobayashi
Objectives To compare the Ki-67 labeling index value obtained through immunohistochemistry analysis by human examiners to that obtained from computer-assisted image analysis, and to establish a cut-off value for Ki-67 labeling index for each method in luminal B breast carcinoma. Methods Immunohistochemistry analysis for Ki-67 was performed on the formalin-fixed, paraffin-embedded tissue samples from 403 patients with primary luminal breast cancers. Whole slide images were obtained using the NanoZoomer (Hamamatsu Photonics, Hamamatsu, Japan) and thoroughly analyzed using the Definiens Tissue Studio version 1.1 (Definiens AG, Munich, Germany) to detect the percentage of positively-stained nuclei of carcinoma cells. Results Although a significant correlation was found between the Ki-67 labeling index obtained by manual assessment and computer-assisted image analysis (Spearman rank correlation coefficient, P < 0.01), the Ki-67 labeling index value obtained by manual assessment was significantly higher than that obtained by computer-assisted image analysis (Wilcoxon signed rank test, P < 0.0001). Disease-free survival was significantly lower in 403 patients with tumors having high Ki-67 labeling index values determined by automated analysis (cut-off value: 11.5%; P < 0.00001) and visual counting (cut-off value: 28.5%; P < 0.00001). Disease-free survival was also significantly lower in 288 patients who received adjuvant endocrine therapy alone having high Ki-67 labeling index values determined by automated analysis (cut-off value: 11.5%; P < 0.0001) and visual counting (cut-off value: 19.7%, P < 0. 0001). Conclusions The Ki-67 labeling index values determined by automated analysis and visual counting could equally predict disease-free survival in patients with luminal B breast carcinoma, including those who received endocrine therapy.

23 August 2024 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
TITsuguo Iwatani
Tsuguo Iwatani
KSKeita Sasaki
Keita Sasaki
RMRyunosuke Machida
Ryunosuke Machida
Tadahiko ShienTadahiko Shien
Tadahiko Shien
FHFumikata Hara
Fumikata Hara
HIHiroji Iwata
Hiroji Iwata
Background: The increasing incidence and prevalence of breast cancer alongside diagnostic and treatment technology advances have produced a debate about the financial burden cancer places on the healthcare system and concerns about access. Methods: This study was conducted at 51 hospitals belonging to the Breast Cancer Study Group of the Japan Clinical Oncology Group using a web-based survey. The survey period conducted from July 2021 to June 2022. The study population included patients with metastatic breast cancer who received the related treatment as their first-line therapy. The proportion of patients who selected that regimen as their first-line treatment was tabulated. The total cost increase for each current standard therapy in comparison to conventional treatments was calculated. Results: A total of 702 patients (pts) were surveyed. Of those enrolled, 342 (48.7%) received high-cost treatment [estimated monthly drug costs exceeding ~500 000 Japanese Yen (JPY)]. Of these, 16 pts (4.7%) were receiving very high-cost treatment, amounting to more than 1 000 000 JPY per month. Fifty three (15.5%) of the patients who received high-cost treatment were 75 years of age or older. Of these, 1 pt (0.3%) were receiving very high-cost treatment. Analyses of incremental costs by current drugs showed that abemaciclib was costly with total additional cost of 6 365 670 JPY per patient. The total additional cost of the regimen per patient that included palbociclib was the second highest at 4011248 JPY, followed by atezolizumab at 3209033 JPY. Conclusions: The findings indicate that evaluating the financial implications of high-cost treatments requires considering not only drug prices but also analysis of total cost increase.

7 November 2011 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
HSHideo Shigematsu
Hideo Shigematsu
TKTakayuki Kadoya
Takayuki Kadoya
YKYoshie Kobayashi
Yoshie Kobayashi
KKKeiko Kajitani
Keiko Kajitani
TSTatsunari Sasada
Tatsunari Sasada
MOMorihito Okada
Morihito Okada
We report a case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy 6 years after primary treatment of triple-negative breast cancer. The primary tumor was negative for HER-2 as determined by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) (1+, and ratio, 1.1), but examination of the recurrent lymph node metastasis showed positivity for HER-2 by FISH (ratio, 5.2). No lesions were detected in either her left breast or in other organs, and the patient was diagnosed as having HER-2-positive recurrent disease. Combination chemotherapy using weekly paclitaxel and trastuzumab was initiated, and a clinically complete response was achieved. This report suggests the benefit of routine evaluation of HER-2 status in recurrent breast cancer with the introduction of HER-2-targeting agents.

28 May 2021 in Breast Cancer
Verified
Journal Article
Open access
PDF file
AAAi Amioka
Ai Amioka
TKTakayuki Kadoya
Takayuki Kadoya
SSSatoshi Sueoka
Satoshi Sueoka
YKYoshie Kobayashi
Yoshie Kobayashi
SSShinsuke Sasada
Shinsuke Sasada
MOMorihito Okada
Morihito Okada
Background: Previously, we reported that Wnt5a-positive breast cancer can be classified as estrogen receptor (ER)-positive breast cancer; its prognosis is worse than that of Wnt5a-negative breast cancer. This study aimed to investigate the mechanisms underlying the poor prognosis in Wnt5a-positive breast cancer patients. Methods: In total, 151 consecutive ER-positive breast cancer patients who underwent resection between January 2011 and February 2014 were enrolled. DNA microarray and pathway analyses were conducted using MCF-7 cells stably expressing Wnt5a [MCF-7/Wnt5a (+)]. Based on the outcomes, cell viability/drug sensitivity assays, and mutation analysis were performed using cell cultures and breast cancer tissues. The relationship between Wnt5a and the PI3K–AKT–mTOR signaling pathway was also examined. Results: The relapse-free survival rate in patients with Wnt5a-positive breast cancer was significantly lower than that in patients with Wnt5a-negative breast cancer (P = 0.047). DNA microarray data suggest that only the cytochrome P450 (CYP) pathway was significantly upregulated in MCF-7/Wnt5a (+) cells (P = 0.0440). Additionally, MCF-7/Wnt5a (+) cells displayed reduced sensitivity to the metabolic substrates of CYP, tamoxifen (P < 0.001), paclitaxel (P < 0.001), and cyclophosphamide (P < 0.001). Of note, PIK3CA mutations were not associated with the expression of Wnt5a in breast cancer tissue and culture cells. Conclusions: In ER-positive breast cancer, Wnt5a upregulates the CYP metabolic pathway and suppresses tamoxifen, paclitaxel, and cyclophosphamide resistance, all of the three, standard treatment methods for ER-positive breast cancer. Wnt5a is thus potentially involved in the poor prognosis of ER-positive breast cancer independently of the PI3K–AKT–mTOR signaling pathway.